Carolyn Brown

1 week ago | recorder.com | Carolyn Brown

E-Edition Advertise Newsletters Subscribe Home News Opinion Sports Business Arts & Life Obituaries Classifieds Calendar Puzzles Florence-based author and illustrator Grace Lin is known for books like “Where the Mountain Meets the Moon” (for which she received a Newbery Honor in 2010), “The Gate, the Girl, and the Dragon,” “The Ugly Vegetables,” and “A Big Mooncake for Little Star” (for which she received a Caldecott Honor in 2019). Now, the Eric Carle Museum of Picture Book Art in Amherst is...

3 weeks ago | medscape.com | Carolyn Brown

Boston Scientific has discontinued production of its ACURATE neo2 heart valves following the release of data showing the devices were linked to higher rates of all-cause death, stroke, and rehospitalization than were other commercially available valves. The company reported the decision in a May 28 regulatory filing.

1 month ago | francais.medscape.com | Carolyn Brown

Les patients ayant reçu un seul traitement antiplaquettaire – généralement de l'aspirine – après un remplacement valvulaire aortique transcathéter (TAVR) avaient un risque de décès dans les 6 mois suivants environ réduit de moitié par rapport aux patients ayant reçu un double traitement antiplaquettaire, selon une étude de terrain. Les résultats étaient similaires chez les hommes et les femmes et chez les patients atteints ou non d'une maladie coronarienne.

1 month ago | portugues.medscape.com | Carolyn Brown

Pacientes que receberam um único tratamento antiplaquetário — geralmente aspirina — após o implante transcateter da válvula aórtica (TAVI) apresentaram cerca de metade do risco de óbito nos seis meses subsequentes em comparação com pacientes que receberam terapia antiplaquetária dupla. Os achados foram semelhantes em homens e mulheres, e em pacientes com e sem doença arterial coronariana.

1 month ago | medscape.com | Carolyn Brown

A transcatheter aortic valve replacement (TAVR) therapy was approved by the US Food and Drug Administration (FDA) for patients with severe aortic stenosis even without symptoms. This is the first FDA approval for TAVR in patients who are asymptomatic. Current clinical guidelines recommend routine surveillance every 6-12 months in patients who aren’t having any symptoms.